clinical trial · NCT06564623
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase1·recruiting·n = 25
Biliary Tract CancersmBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]DurvalumabTremelimumab
brief summary
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.
started
May 27, 2025
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
May 8, 2026
official title
A Pilot Study of Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol